CLVT

CLARIVATE PLC
NYSETECHNOLOGYINFORMATION TECHNOLOGY SERVICES

Key Statistics

Market Cap
$1.13B
P/E Ratio
—
EPS
$-0.52
Beta
1.40
52W High
$3.87
52W Low
$1.42
50-Day MA
$1.85
200-Day MA
$2.31
Dividend Yield
—
Profit Margin
-13.80%
Forward P/E
2.56
PEG Ratio
0.17

About CLARIVATE PLC

Clarivate Plc, an information services and analytics company, provides analysis and structured information for the discovery, protection and commercialization of scientific research, innovations and brands. The company is headquartered in London, the United Kingdom.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$2.41B
Gross Profit (TTM)$1.61B
EBITDA$914.80M
Operating Margin6.13%
Return on Equity-7.01%
Return on Assets0.94%
Revenue/Share (TTM)$3.71
Book Value$7.09
Price-to-Book0.26
Price-to-Sales (TTM)0.47
EV/Revenue2.159
EV/EBITDA7.82
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)-5.50%
Shares Outstanding$639.22M
Float$468.64M
% Insiders18.33%
% Institutions93.10%

Historical Volatility

HV 10-Day
64.01%
HV 20-Day
63.64%
HV 30-Day
60.05%
HV 60-Day
66.43%
HV Rank
50.0%

Volatility is currently expanding

Analyst Ratings

Consensus ($2.97 target)
2
Buy
5
Hold
1
Strong Sell

Latest News

Sterne Kessler and Clarivate Announce Partnership to Develop AI-enhanced Patent Workflow Solutions

WASHINGTON--(BUSINESS WIRE)--Sterne, Kessler, Goldstein & Fox (Sterne Kessler), a market leading intellectual property (IP) law firm, today announced a co-development partnership with Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, to develop AI-enhanced patent workflow solutions. This partnership brings together Sterne Kessler's practitioner-built technology and deep patent practice expertise with Clarivate's leading IP data and software. Together, the.

Business Wire10/15/2026Neutral
Clarivate Completes Sale of Life Sciences & Healthcare Segment, Advances Strategic Transformation

Transaction sharpens strategic focus on leading Academia & Government and Intellectual Property segments Proceeds strengthen balance sheet and enhance financial flexibility LONDON, Oct. 6, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) ("Clarivate" or the "Company"), a leading global provider of transformative intelligence, today announced the successful completion of the sale of its Life Sciences & Healthcare segment to Altaris, LLC ("Altaris"), advancing Clarivate's transformation and simplifying its portfolio. The transaction for $600 million was previously announced on July 6, 2026.

PRNewsWire10/6/2026Neutral
Clarivate Announces Final Results of Offer to Purchase for Cash Certain of its Outstanding Debt Securities

LONDON, Sept. 24, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) ("Clarivate"), a leading global provider of transformative intelligence, today announced the expiration and final results of its previously announced cash tender offer (the "Offer") by its wholly-owned subsidiary, Clarivate Science Holdings Corporation (the "Company"), to purchase the outstanding 3.875% Senior Secured Notes due 2028 (the "Notes") for aggregate principal amount of up to $75,000,000 (the "Maximum Amount"), upon the terms and subject to the conditions set forth in the Offer to Purchase dated September 17, 2026 (the "Offer to Purchase") and any related documents (collectively with the Offer to Purchase, the "Tender Offer Documents").

PRNewsWire9/24/2026Neutral
Clarivate Announces Pricing Terms of Offer to Purchase for Cash Certain of its Outstanding Debt Securities

LONDON, Sept. 23, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) ("Clarivate"), a leading global provider of transformative intelligence, today announced the Reference Yield and Total Consideration (as set forth in the table below) to be paid in connection with its previously announced cash tender offer (the "Offer") by its wholly-owned subsidiary, Clarivate Science Holdings Corporation (the "Company"), to purchase the outstanding notes described below, upon the terms and subject to the conditions set forth in the Offer to Purchase dated September 17, 2026 (the "Offer to Purchase").

PRNewsWire9/23/2026Neutral
Clarivate to Report Third Quarter 2026 Results on November 3, 2026

LONDON, Sept. 22, 2026 /PRNewswire/ -- (PR Newswire) - Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced it will report its financial results for the third quarter 2026 before the market opens on Tuesday, November 3, 2026.

PRNewsWire9/22/2026Neutral
Clarivate Commences Offer to Purchase for Cash Certain of its Outstanding Debt Securities

NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) ("Clarivate"), a leading global provider of transformative intelligence, today announced that its wholly-owned subsidiary, Clarivate Science Holdings Corporation (the "Company"), has commenced a cash tender offer (the "Offer") to purchase the outstanding notes described below, upon the terms and subject to the conditions set forth in the Offer to Purchase dated September 17, 2026 (the "Offer to Purchase").

PRNewsWire9/17/2026Neutral
Clarivate Reveals Citation Laureates 2026 Recognizing Transformative Scientific Breakthroughs

22 researchers honored for Nobel-class discoveries, including pioneers of GLP-1 medicines and other world-changing advances LONDON, Sept. 17, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced the Citation Laureates 2026, a distinguished group of 22 researchers whose work is of Nobel class.

PRNewsWire9/17/2026Neutral
Accuserve Solutions Appoints Maroun S. Mourad as an Independent Board Member

Veteran Insurance Executive Brings Carrier Relationships and Data Analytics Expertise  to Support Accuserve's Continued Growth and Its Mission to Simplify the Claims Experience DENVER, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Accuserve Solutions (“Accuserve” or the “Company”), an independent managed repair services platform connecting insurance carriers, homeowners, and contractors, today announced the appointment of Maroun S.

GlobeNewsWire9/1/2026Neutral
Clarivate Scales Agentic AI Across Cortellis to Advance Drug Development

Expanded capabilities across Cortellis portfolio help life sciences organizations turn trusted intelligence into action and accelerate decision making across the research and development lifecycle LONDON, Aug. 6, 2026 /PRNewswire/ --  Clarivate Plc  (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the expansion of agentic AI capabilities across the Cortellis portfolio, helping life sciences R&D teams accelerate discovery, strengthen safety assessment and make faster, more informed portfolio decisions. By embedding AI directly within existing workflows, the new capabilities enable researchers to reduce manual effort, navigate complexity and focus on higher-value scientific and strategic decisions.

PRNewsWire8/6/2026Neutral
Clarivate Q2 Earnings Call Highlights

Clarivate NYSE: CLVT said during its earnings call that it expects organic recurring revenue and annualized contract value growth to improve in the second half of the year, citing renewal visibility, product momentum and a growing pipeline of AI-enabled offerings.

MarketBeat7/29/2026Positive

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CLVT and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More TECHNOLOGY Stocks

Data last updated: 10/17/2026